Cargando…

The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan

BACKGROUND: Endothelin A receptor antagonists (ET(A)RA) slow chronic kidney disease (CKD) progression but their use is limited due to fluid retention and associated clinical risks. Sodium–glucose co-transporter 2 inhibitors (SGLT2i) cause osmotic diuresis and improve clinical outcomes in CKD and hea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veenit, Vandana, Heerspink, Hiddo J L, Ahlström, Christine, Greasley, Peter J, Skritic, Stanko, van Zuydam, Natalie, Kohan, Donald E, Hansen, Pernille B L, Menzies, Robert I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539223/ https://www.ncbi.nlm.nih.gov/pubmed/37102226 http://dx.doi.org/10.1093/ndt/gfad078

Ejemplares similares

Zibotentan, an Endothelin A Receptor Antagonist, Prevents Amyloid-β-Induced Hypertension and Maintains Cerebral Perfusion
por: Palmer, Jennifer C., et al.
Publicado: (2020)

Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?
por: Chung, Edmund Y. M., et al.
Publicado: (2022)

Endothelin and Endothelin Antagonists in Chronic Kidney Disease
por: Kohan, Donald E., et al.
Publicado: (2014)

Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
por: Yeoh, Su Ern, et al.
Publicado: (2023)

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
por: Koshino, Akihiko, et al.
Publicado: (2023)

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
por: Dekkers, Claire C. J., et al.
Publicado: (2019)

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease
por: Smeijer, J. David, et al.
Publicado: (2023)

Targeting the Endothelin A Receptor in IgA Nephropathy
por: Kohan, Donald E., et al.
Publicado: (2023)

Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baseline
por: Stefánsson, Bergur V., et al.
Publicado: (2021)

A metabolomics‐based molecular pathway analysis of how the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes
por: Mulder, Skander, et al.
Publicado: (2020)

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials
por: Koomen, Jeroen V., et al.
Publicado: (2020)

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment
por: Mercier, Anne-Kristina, et al.
Publicado: (2023)

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
por: Scholtes, Rosalie A., et al.
Publicado: (2021)

Endothelin Receptors and Their Antagonists()()
por: Maguire, Janet J., et al.
Publicado: (2015)

The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
por: Provenzano, Michele, et al.
Publicado: (2021)

Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial
por: Morrow, Andrew J, et al.
Publicado: (2020)

Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND
por: Sen, Taha, et al.
Publicado: (2022)

The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet
por: Scholtes, Rosalie A., et al.
Publicado: (2022)

Exposure–response relationships for the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin with regard to renal risk markers
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2020)

Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers
por: Idzerda, Nienke M A, et al.
Publicado: (2019)

Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

The Role of Endothelin-1 and Endothelin Receptor Antagonists in Inflammatory Response and Sepsis
por: Kowalczyk, Agata, et al.
Publicado: (2014)

Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease
por: van der Aart-van der Beek, Annemarie B., et al.
Publicado: (2021)

Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial
por: Vart, Priya, et al.
Publicado: (2023)

Endothelin Receptor Antagonists in Kidney Disease
por: Martínez-Díaz, Irene, et al.
Publicado: (2023)

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies
por: Tomkinson, Helen, et al.
Publicado: (2011)

Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial
por: Stern, Edward P., et al.
Publicado: (2022)

Endothelin
por: Davenport, Anthony P., et al.
Publicado: (2016)

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
por: Dekkers, Claire C J, et al.
Publicado: (2018)

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
por: Dekkers, Claire C J, et al.
Publicado: (2018)

Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors
por: Eickhoff, Mie K., et al.
Publicado: (2019)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
por: Wheeler, David C, et al.
Publicado: (2021)

Antidiuretic Effects of the Endothelin Receptor Antagonist Avosentan
por: Baltatu, Ovidiu Constantin, et al.
Publicado: (2012)

Iontophoresis of Endothelin Receptor Antagonists in Rats and Men
por: Roustit, Matthieu, et al.
Publicado: (2012)

Endothelin antagonists in subarachnoid hemorrhage: what next?
por: Macdonald, R Loch
Publicado: (2012)

Evidence for biased agonists and antagonists at the endothelin receptors
por: Maguire, Janet J.
Publicado: (2016)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
por: Chertow, Glenn M., et al.
Publicado: (2023)

Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells
por: Peduto Eberl, L, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_s9qvl4if2sdir81vsgq4tu84le